• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BOSTON SCIENTIFIC CORPORATION ELUVIA DRUG-ELUTING VASCULAR STENT SYSTEM; STENT, SUPERFICIAL FEMORAL ARTERY, DRUG-ELUTING

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BOSTON SCIENTIFIC CORPORATION ELUVIA DRUG-ELUTING VASCULAR STENT SYSTEM; STENT, SUPERFICIAL FEMORAL ARTERY, DRUG-ELUTING Back to Search Results
Model Number 24653
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem No Clinical Signs, Symptoms or Conditions (4582)
Event Date 12/01/2023
Event Type  Death  
Manufacturer Narrative
A1: patient id: (b)(6).A2: patient age: 73 years old at time of enrollment.
 
Event Description
Elegance clinical study.It was reported that the subject passed away.On (b)(6) 2023, the subject underwent treatment with eluvia drug eluting stents as part of the elegance clinical trial.The target lesion was located in the 100% stenosed left proximal superficial femoral artery (sfa) extending up to the left mid-sfa; with a 5 mm proximal reference vessel diameter, and a 5 mm distal reference vessel diameter, with a 240 mm lesion length.The lesion was classified as transatlantic intersociety consensus (tasc) ii c lesion.Prior to the treatment of the target lesion with the study devices, pre-dilation was performed using 6 mm x 150 mm and 5 mm x 120 mm percutaneous transluminal angioplasty balloon.Treatment of the target lesion was then performed by placement of two 6 mm x 120 mm drug eluting stents, and one 6 mm x 40 mm eluvia drug eluting stent.Post procedure, the final residual stenosis was noted to be 0%.On (b)(6) 2023, the subject was discharged from the hospital on dual anti-platelet therapy.On approximately (b)(6) 2023, the subject passed away.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ELUVIA DRUG-ELUTING VASCULAR STENT SYSTEM
Type of Device
STENT, SUPERFICIAL FEMORAL ARTERY, DRUG-ELUTING
Manufacturer (Section D)
BOSTON SCIENTIFIC CORPORATION
300 boston scientific way
marlborough MA 01752
Manufacturer (Section G)
BOSTON SCIENTIFIC CORPORATION
ballybrit business park
galway
EI  
Manufacturer Contact
rachel shields
4100 hamline ave n
arden hills, MN 55112
6512422111
MDR Report Key18907512
MDR Text Key337703142
Report Number2124215-2024-15173
Device Sequence Number1
Product Code NIU
Combination Product (y/n)Y
Reporter Country CodeCH
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Other,Foreign,Study,Health Professional,Company Representative
Reporter Occupation Physician
Type of Report Initial
Report Date 03/14/2024
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received03/14/2024
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Model Number24653
Device Catalogue Number24653
Device Lot Number0029684507
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received02/23/2024
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured06/10/2022
Is the Device Single Use? Yes
Type of Device Usage Initial
Patient Sequence Number1
Treatment
ELUVIA DRUG ELUTING VASCULAR STENTS
Patient Outcome(s) Death;
Patient SexMale
Patient RaceAsian
-
-